News Archives

March 16, 2023

ASH 2022: Dr. Jennifer Woyach on Pirtobrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with a BTK Inhibitor

Pirtobrutinib continues to demonstrate promising and durable efficacy in heavily pre-treated patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), who have been previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. Pirtobrutinib may be an important option to extend the benefit of BTK inhibition among patients

March 16, 2023

ASH 2022: Dr. Paolo Ghia on Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) who Received First-Line Treatment with Ibrutinib

Targeted therapies have greatly improved survival outcomes for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). For example, Ibrutinib is so effective at controlling CLL / SLL that the overall survival of patients treated with first-line ibrutinib is no different from that of the general population.

March 16, 2023

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with Undetectable Measurable Residual Disease (MRD) After Treatment with Ibrutinib Plus Venetoclax

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who achieved undetectable measurable (or minimal) residual disease (uMRD) after fixed-duration ibrutinib + venetoclax treatment continue to have excellent outcomes four years after stopping initial therapy. The results of this study suggest that if patients achieve uMRD remission,

March 6, 2023

CLL Society’s COVID-19 Update for the Week of March 6, 2023

Here is your March 6, 2023 weekly COVID-19 update of what has been happening this past week in the United States.

March 1, 2023

Navigating the Financial Aspects of CAR T-Cell Therapy

In this WebMD article, Dr. Koffman provides practical advice on how patients can receive assistance paying for this expensive and potentially lifesaving therapy.

February 23, 2023

ASH 2022: Dr. Tahla Munir on Predicting Responses to Combination Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

For patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the response to combination ibrutinib plus venetoclax treatment in the first two months seems to predict who will have deep, sustained responses.

February 23, 2023

ASH 2022: Dr. Talha Munir on How IgHV Mutation Status in Chronic Lymphocytic Leukemia (CLL) Affects Response to Taking Ibrutinib in Combination with Venetoclax

In this study, patients with IGHV unmutated chronic lymphocytic leukemia (CLL) responded better to combination ibrutinib + venetoclax than patients with IGHV mutated CLL and were more likely to achieve measurable residual disease (MRD) negativity in the peripheral blood and bone marrow.

February 23, 2023

ASH 2022: Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab, Ibrutinib, and Venetoclax in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

Fixed duration combination therapy of obinutuzumab, ibrutinib, and venetoclax with treatment adjustment based on clinical response and results of measurable residual disease testing shows high efficacy and safety for the front-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients with del (17p) or TP53 mutation offering exciting hope

February 20, 2023

CLL Society’s COVID-19 Update for the Week of February 20, 2023

Please read this week’s February 20,2023 update which is pertinent to all of those who are immunocompromised, including anyone living with CLL / SLL regardless of treatment status.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News

ASH 2022: Dr. Jennifer Woyach on Pirtobrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with a BTK Inhibitor

ASH 2022: Dr. Paolo Ghia on Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) who Received First-Line Treatment with Ibrutinib

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with Undetectable Measurable Residual Disease (MRD) After Treatment with Ibrutinib Plus Venetoclax

CLL Society’s COVID-19 Update for the Week of March 6, 2023

Navigating the Financial Aspects of CAR T-Cell Therapy

ASH 2022: Dr. Tahla Munir on Predicting Responses to Combination Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Dr. Talha Munir on How IgHV Mutation Status in Chronic Lymphocytic Leukemia (CLL) Affects Response to Taking Ibrutinib in Combination with Venetoclax

ASH 2022: Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab, Ibrutinib, and Venetoclax in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

CLL Society’s COVID-19 Update for the Week of February 20, 2023

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT